联交所上市委员会已批准超额配发股份上市及买卖。预期超额配发股份将于2026年1月21日(星期三)上 午九时正开始在联交所主板上市及买卖。 格隆汇1月16日丨英矽智能(03696.HK)宣布，保荐人兼整体协调人(为其本身及代表国际承销商)已于 2026年1月16日(星期五)悉数行使招股章程所述的超额配股权，涉及合共14,203,500股股份(「超额配发股 份」)，占全球发售项下初步可供认购发售股份总数的约15%(于行使超额配股权之前)。 超额配发股份将由公司按每股股份24.05港元(即全球发售项下每股股份的发售价，不包括1.0%经纪佣 金、0.0027%证监会交易徵费、0.00565%联交所交易费及0.00015%会财局交易徵费)发行及配发。超额 配发股份将用于促成向Aleksandrs Zavoronkovs先生归还Aleksandrs Zavoronkovs与MORGANSTANLEY & CO INTERNATIONAL PLC订立的日期为2025年12月24日的借股协议项下用于补足国际发售项下超额分 配的14,203,500股借入股份。 ...

智通财经APP讯，英硅智能(03696)发布公告，保荐人兼整体协调人(为其本身及代表国际承销商)已于 2026年1月16日悉数行使招股章程所述的超额配股权，涉及合共1420.35万股股份，占全球发售项下初步 可供认购发售股份总数的约15%(于行使超额配股权之前)。超额配发股份将由公司按每股股份24.05港元 发行及配发。超额配发股份将用于促成向Aleksandrs Zavoronkovs先生归还Aleksandrs Zavoronkovs先生 与MORGAN STANLEY & CO INTERNATIONAL PLC订立的日期为2025年12月24日的借股协议项下用 于补足国际发售项下超额分配的1420.35万股借入股份。 ...

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示 概不就因本公告全部或任何部分內容而產生或因依賴該等內容引致的任何損失承擔任何責任。 除非本公告另有界定，否則本公告所用詞彙與英矽智能（「本公司」）日期為2025年12月18日的 招股章程（「招股章程」）所界定者具有相同涵義。 本公司宣佈保薦人兼整體協調人（為其本身及代表國際承銷商）已於2026年1月 16日（星期五）悉數行使招股章程所述的超額配股權，涉及合共14,203,500股股 份（「超額配發股份」），佔全球發售項下初步可供認購發售股份總數的約15%（於 行使超額配股權之前）。 超額配發股份將由本公司按每股股份24.05港元（即全球發售項下每股股份的 發售價，不包括1.0%經紀佣金、0.0027%證監會交易徵費、0.00565%聯交所 交易費及0.00015%會財局交易徵費）發行及配發。超額配發股份將用於促成 向Aleksandrs Zavoronkovs先生歸還Aleksandrs Zavoronkovs先生與MORGAN STAN ...

Core Viewpoint - The stock of Insilico Medicine (03696) surged over 12% to a high of HKD 59.85, representing an increase of nearly 150% from its IPO price of HKD 24.05, with a current trading price of HKD 58.65 and a trading volume of HKD 1.81 billion [1] Group 1 - Insilico Medicine has entered into a research collaboration with Servier worth USD 888 million, focusing on utilizing its AI platform Pharma.AI to identify and develop new therapeutic drugs targeting challenging oncology areas [1] - The company announced the completion of the first patient dosing in a Phase IIa clinical trial named BETHESDA for its innovative PHD inhibitor ISM5411, which was developed with the assistance of Pharma.AI [1] Group 2 - According to a report from Zheshang Securities, the core value of AI in drug development lies in significantly enhancing the efficiency of early-stage drug research, with Insilico Medicine's Pharma.AI reducing the time from target discovery to clinical candidate confirmation from 4.5 years to 12-18 months, thereby improving the return on investment in the early research phase [1] - The report highlights that several domestic AI drug development platforms have leading global service capabilities, and the ongoing rapid expansion of overseas business has been validated, with a focus on companies like Insilico Medicine [1]

Group 1 - The core viewpoint of the article highlights the significant rise in the stock price of Insilico Medicine (03696), which surged over 12% to a high of HKD 59.85, representing an increase of nearly 150% from its IPO price of HKD 24.05 [1] - Insilico Medicine has entered into a research collaboration with Schwabe, amounting to USD 888 million, focusing on utilizing its AI platform Pharma.AI to identify and develop new therapeutic drugs targeting challenging oncology areas [1] - The company has completed the first dosing of a subject in its Phase IIa clinical trial for its innovative PHD inhibitor ISM5411, which was developed with the assistance of Pharma.AI [1] Group 2 - Zheshang Securities (601878) reported that the core value of AI in drug development significantly enhances early research efficiency, citing that Insilico Medicine's Pharma.AI can reduce the time from target discovery to preclinical candidate confirmation from 4.5 years to 12-18 months, greatly improving the return on investment in the early research phase [1] - The report also notes that several domestic AI drug development platforms have globally leading service capabilities, with ongoing rapid expansion in overseas markets, highlighting a focus on companies like Insilico Medicine [1]

Core Viewpoint - The AI healthcare sector in Hong Kong is experiencing a strong bullish trend, driven by clear industry trends and significant market demand for AI health solutions [1] Group 1: Market Performance - Alibaba Health has surged over 13%, leading the market with a cumulative increase of over 46% this month [1] - Other notable performers include Yidu Tech with a rise of over 9%, MicroPort Robotics up by 8.9%, and Ping An Good Doctor increasing by over 4% [1] - Additional companies such as Yimaitong, JD Health, and Gushengtang also saw gains [1] Group 2: Industry Drivers - The launch of Ant Group's AI health assistant "Antifufu" has seen monthly active users exceed 30 million, with daily inquiries surpassing 10 million, indicating strong demand in the health AI sector [1] - OpenAI's introduction of "ChatGPT Health" on January 8 further emphasizes the confidence of leading AI companies in the health AI market [1] Group 3: Market Forecast - Frost & Sullivan predicts that China's "AI + healthcare" market will grow from 8.8 billion yuan in 2023 to 315.7 billion yuan by 2033, with a compound annual growth rate of 43.1% over the next decade [1] - Huafu Securities reports that the AI healthcare industry is entering a critical phase of commercialization, supported by national strategies and market demand [1] - The report highlights a closed-loop demand for AI applications, which will sustain the continuous development of the AI industry [1]

Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, indicating a "Buy" rating based on recent market performance and emerging opportunities in innovative drug development [2][3]. Core Insights - The pharmaceutical sector saw a significant increase, with the Shenwan Pharmaceutical and Biological Index rising by 7.8%, outperforming the Shanghai Composite Index, which increased by 3.82% [2][3]. - The report highlights the ongoing commercialization of innovative drugs, including the oral GLP-1 medication Wegovy by Novo Nordisk, and the successful clinical trials of various RNAi therapies [11][13][18]. - The establishment of a comprehensive long-term care insurance system in China is expected to enhance the healthcare landscape, potentially benefiting the pharmaceutical sector [11][12]. Market Performance - The Shenwan Pharmaceutical and Biological Index ranked 6th among 31 Shenwan first-level sub-industries, with various sub-sectors showing positive growth, such as medical devices (+10.8%) and medical research outsourcing (+11.1%) [2][5]. - The overall valuation of the pharmaceutical sector stands at 30.6 times earnings, ranking 10th among 31 Shenwan first-level industries [5][10]. Recent Key Events - The report notes the successful approval and commercialization of several new drugs, including BeiGene's BCL-2 inhibitor and Sanofi's APOC3 siRNA drug, which address significant medical needs [20][22]. - Collaborations in drug development are highlighted, such as the $8.88 billion partnership between Insilico Medicine and Servier focusing on oncology [21]. - The report emphasizes the potential of the brain-computer interface industry, with companies like Mindray Medical and Lepu Medical making strides in this area [24]. Investment Opportunities - The report suggests focusing on domestic innovative drug companies and CROs, particularly those involved in the development of small nucleic acid drugs and brain-computer interface technologies [2][11]. - Specific companies to watch include Tigermed, WuXi AppTec, and Innovent Biologics, which are positioned to benefit from the recovery of the innovative drug sector [2][11].

Group 1: Market Performance - The Hang Seng Index rose by 0.86%, gaining 224 points to close at 26,456 points, while the Hang Seng Tech Index increased by 2.08% [1] - The early trading volume in the Hong Kong stock market reached HKD 168.4 billion [1] Group 2: AI and Technology Sector - Leading AI model companies saw significant gains, with MINIMAX-WP (00100) up over 31% and Zhiyun (02513) rising by 30% due to a strategic partnership with Didi [1] - Other AI-related stocks also performed well, including Mifengshi (02556) which rose by 18%, and AI pharmaceutical companies like Yingshi Intelligent (03696) up 12% and Yidu Tech (02158) up over 8% [1] - Kuaishou-W (01024) increased by 5.62%, with expectations of significant revenue growth in FY2026 due to its AI initiatives [1] - Kingdee International (00268) rose by 10.71%, benefiting from accelerated AI model integration in industrial processes [1] Group 3: Lithium Industry - Tianqi Lithium (09696) and Ganfeng Lithium (01772) saw increases of over 5% and 6% respectively, driven by export tax adjustments that may stimulate demand [1] Group 4: New Listings and Stock Movements - The new stock Hao Wei Group (00501) debuted with a 15% increase, recognized as a leading Fabless semiconductor design company [2] - LFG Investment Holdings (03938) resumed trading and surged over 120% following a cash offer from Chen Shaoyang at a significant discount [2] Group 5: Regulatory Impact on Companies - Contemporary Amperex Technology Co., Ltd. (Ningde Times) fell by 2.94% due to new battery export tax policies and rising lithium carbonate prices [3] - Smoore International (06969) declined by 1.87% as the export tax rebate for electronic cigarettes is set to be canceled, potentially impacting profits [4]

Group 1 - The Hang Seng Index rose by 0.86%, gaining 224 points to close at 26,456 points, while the Hang Seng Tech Index increased by 2.08%. The morning trading volume reached HKD 168.4 billion [1] - Companies involved in AI large models saw significant gains, with MINIMAX-WP (00100) up over 31%, and Zhiyun (02513) rising by 30% after a strategic partnership with Didi to explore mobility agent scenarios [1] - The AI pharmaceutical sector also benefited from the surge in AI large models, with companies like Yingshi Intelligent (03696) up 12%, and Yidu Tech (02158) increasing by over 8% [1] Group 2 - Kuaishou-W (01024) increased by 5.62%, with its AI initiatives expected to significantly boost revenue for the fiscal year 2026 [2] - Kingdee International (00268) rose by 10.71%, driven by accelerated full-process empowerment through industrial large models and the implementation of multi-agent collaboration in its AI Starry Sky suite [3] - New stock Haowei Group (603501) (00501) debuted with a 15% increase, recognized as a leading Fabless semiconductor design company [4] Group 3 - LFG Investment Holdings (03938) resumed trading and surged over 120% following a cash offer from Chen Shaoyang at a discount of approximately 59.46% [5] - Contemporary Amperex Technology Co., Ltd. (300750) (03750) fell by 2.94% due to the introduction of a new battery export tax rebate policy, while lithium carbonate prices continued to rise [6] - Smoore International (06969) declined by 1.87% as the export tax rebate for electronic cigarettes is set to be canceled, potentially impacting the profits of related companies [7]

Core Viewpoint - The AI-driven drug discovery and development company Insilico Medicine (3696.HK) experienced a significant intraday increase of 17%, reaching a new high of 55 HKD, marking a cumulative increase of over 52% since its listing, with a market capitalization exceeding 30 billion HKD [1] Company Summary - Insilico Medicine's stock price surged to a peak of 55 HKD, reflecting strong investor interest and confidence in its AI-driven drug development capabilities [1] - The company has achieved a remarkable cumulative gain of over 52% since its initial public offering, indicating robust market performance [1] - With a market capitalization surpassing 30 billion HKD, Insilico Medicine is positioned as a significant player in the biotechnology sector [1]